BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211209
DTEND;VALUE=DATE:20211211
DTSTAMP:20260504T133350
CREATED:20210920T181851Z
LAST-MODIFIED:20210920T181851Z
UID:5588-1639008000-1639180799@carb-x.org
SUMMARY:Infection 2021: British Society for Antimicrobial Chemotherapy (BSAC) Winter Conference
DESCRIPTION:Join us as we celebrate 50 years of BSAC! Infection 2021 is an exciting two-day hybrid conference looking at the challenges and future of infection management and how we can rise the meet the challenge of antimicrobial resistance. \nWe encourage you to register for either in-person or virtual attendance and submit your abstracts for consideration for oral and poster presentation.  All accepted abstracts will be published in JAC-Antimicrobial Resistance. \nCARB-X participants include Kevin Outterson\, Executive Director\, who will be leading the session “The potential of de-linkage in addressing antimicrobial resistance” on Friday December 10th. \nClick here to learn more.\nClick here to view the agenda.
URL:https://carb-x.org/event/infection-2021-british-society-for-antimicrobial-chemotherapy-bsac-winter-conference/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211208
DTEND;VALUE=DATE:20211210
DTSTAMP:20260504T133350
CREATED:20211116T181031Z
LAST-MODIFIED:20211116T181031Z
UID:5654-1638921600-1639094399@carb-x.org
SUMMARY:ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
DESCRIPTION:The 2021 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance will take place online\, Dec. 8-9\, 2021.  \n\n\nAntimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority by national and international bodies. Co-sponsored by the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID)\, this multidisciplinary meeting will address the challenges\, opportunities and current requirements for antimicrobial drug development to address antimicrobial resistance.\n\n\n\nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/asm-escmid-joint-conference-on-drug-development-to-meet-the-challenge-of-antimicrobial-resistance/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211123T070000
DTEND;TZID=America/New_York:20211123T080000
DTSTAMP:20260504T133350
CREATED:20211118T193239Z
LAST-MODIFIED:20211118T193420Z
UID:5664-1637650800-1637654400@carb-x.org
SUMMARY:AMR Industry Alliance Panel on Supporting the Optimal Use of Antimicrobial Medicines through Innovation
DESCRIPTION:This year’s WAAW will take place 18-24 November 2021\, with the theme “Spread Awareness\, Stop Resistance”. You can read more about WHO’s WAAW campaign here. \nThe AMR Industry Alliance virtual panel session will be organized as short dialogues among experts from the public\, private\, academic and civil society sectors who will discuss key topics related to the optimal use of antimicrobial medicines as a means of controlling the spread of antimicrobial resistance (AMR). \nThe three short dialogues will focus on the following topics: \n\nThe role of diagnostics in guiding optimal use of antibiotics\nRelevance of AMR stewardship in achieving the UN SDGs\nStop resistance! Collaborative approaches to tackling AMR\n\nSpeakers include: \n\nHanan H. Balkhy\, Assistant-Director-General\, AMR\, WHO\nThomas Cueni\, Chair\, AMR Industry Alliance & Director-General\, IFPMA\nOtridah Kapona\, National AMR Focal Point and Coordinator\, Zambia National Public Health Institute\, WHO STAG-AMR\nCecilia Ferreyra\, Head of AMR Programme\, FIND\nMukesh Kapila\, Global Health and Humanitarian Affairs\, University of Manchester\, WHO STAG-AMR\nLiz Tayler\, Team Leader\, Monitoring and National Action Plans AMR\, WHO\nScott Weese\, Professor\, Ontario Veterinary College and Director\, Centre for Public Health and Zoonoses\, University of Guelph\nKevin Outterson\, Executive Director\, CARB-X\nPilar Ramon Pardo\, AMR Advisor\, PAHO\nPeter Beyer\, Senior Advisor and Team Lead\, AMR\, WHO\nJean-Louis Tissier\, Vice-President\, Public and Government Affairs\, BioMérieux\nAdam Zerda\, Director\, AMR Strategy and Program Development\nGreg Frank\, Director\, Global Public Policy\, Merck\n\nClick here to learn more.\nClick here to register.
URL:https://carb-x.org/event/amr-industry-alliance-panel-on-supporting-the-optimal-use-of-antimicrobial-medicines-through-innovation/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211119T140000
DTEND;TZID=America/New_York:20211119T150000
DTSTAMP:20260504T133350
CREATED:20211026T161854Z
LAST-MODIFIED:20211026T161854Z
UID:5639-1637330400-1637334000@carb-x.org
SUMMARY:McGill AMR Innovation Summit
DESCRIPTION:Antimicrobials in the era of AMR\nDuring World Antimicrobial Awareness Week (Nov. 18-24 2021)\, the McGill AMR Centre and Innovation + Partnership office are hosting the inaugural McGill AMR Innovation Summit\, a virtual event aimed at discussing antimicrobial R&D and building collaborations and partnerships between McGill scientists and non-academic stakeholders. \nProgram\n\n14:00-14:30 Keynote speaker Erin Duffy\, PhD (public event)\n14:30-15:00 Panel discussion (public event)\n15:00-16:00 Industry-Academic networking event (private event)\n\nKeynote speaker Erin Duffy\, PhD\, Chief of R&D\, CARB-X\nCARB-X is a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. With up to US$480 million to invest in 2016-22\, CARB-X portfolio is the world’s largest early development pipeline in AMR. \nPanel discussion Challenges and opportunities for antimicrobial R&D in the era of AMR\nWith experts from industry and academia. \n• David Claveau\, PhD\, Director\, Medical Affairs at AVIR Pharma\n• Erin Duffy\, PhD\, Chief of Research & Development\, CARB-X\n• Joseph Mancini\, PhD\, Head of Pharmacology and Biologics\, Senior Director at adMare BioInnovations\n• Nicolas Moitessier\, PhD\, Professor in Chemistry (McGill)\, co-founder of Molecular Forecaster\n• Martin Schmeing\, PhD\, Professor in Biochemistry (McGill)\, Director of Centre for Structural Biology\n• Christopher Tan\, PhD\, Director\, Business Development & Licensing\, Search & Evaluation\, Infectious Diseases & Vaccines at Merck Research Laboratories \nRegistration is free but required. \nIf you have any questions\, please contact us at amrcentre@mcgill.ca \nClick here to learn more.\nClick here to register.
URL:https://carb-x.org/event/mcgill-amr-innovation-summit/
LOCATION:VIRTUAL EVENT
ORGANIZER;CN="McGill University":MAILTO:amrcentre@mgcill.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211116T080000
DTEND;TZID=America/New_York:20211116T093000
DTSTAMP:20260504T133350
CREATED:20211014T205847Z
LAST-MODIFIED:20211014T205847Z
UID:5629-1637049600-1637055000@carb-x.org
SUMMARY:EFPIA - Pandemic Prevention: how Europe can lead the fight against AMR
DESCRIPTION:You’re invited to join this virtual event on Tuesday\, 16 November\, 2021 at 14:00 – 15:30 CET. \nThe COVID-19 pandemic took the world by surprise. An AMR induced pandemic will not.\nThe World Bank estimates that 10 million people per year could die if new antimicrobials are not found. Without effective prevention and treatment of infections\, medical procedures such as organ transplantation\, cancer chemotherapy\, and major surgery will become too dangerous to perform. In the Pharmaceutical Strategy for Europe\, the European Commission declared that “new business models are required” if we are to meet this challenge and succeed\, spotlighting 2022 as the year when change needs to happen.\n\nJoin us to discuss how we can drive investment in antimicrobials R&D and set out a roadmap to a sustainable innovation ecosystem that will safeguard society against the threat of AMR.\n  \nCARB-X participants include Kevin Outterson\, Executive Director. \nClick here to learn more and register.
URL:https://carb-x.org/event/efpia-pandemic-prevention-how-europe-can-lead-the-fight-against-amr/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211004
DTEND;VALUE=DATE:20211016
DTSTAMP:20260504T133350
CREATED:20210805T182846Z
LAST-MODIFIED:20210805T182846Z
UID:5546-1633305600-1634342399@carb-x.org
SUMMARY:Vaccinology in Africa Course 4-15 October 2021 (Online)
DESCRIPTION:The course provides state-of-the-art teaching in both human and veterinary vaccinology\, drawing on the experience of the Jenner Institute at the University of Oxford\, The Pirbright Institute\, and this year’s African host\, the KEMRI Wellcome Trust Research Programme in Kenya.  These courses alternate between East and West Africa. In 2021\, participation is limited to attendants currently working or studying in East Africa.    Applications close 31 August 2021. \nClick here to learn more.
URL:https://carb-x.org/event/vaccinology-in-africa-course-4-15-october-2021-online/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210928
DTEND;VALUE=DATE:20211001
DTSTAMP:20260504T133350
CREATED:20210805T182720Z
LAST-MODIFIED:20210805T182720Z
UID:5547-1632787200-1633046399@carb-x.org
SUMMARY:The Vaccines Against Shigella and ETEC (VASE) Conference
DESCRIPTION:This is an international gathering dedicated to developing Shigella and enterotoxigenic Escherichia coli (ETEC) vaccines\, hosted by PATH\, a global nonprofit dedicated to achieving health equity. \nRegistration is now open for the VASE Virtual Symposium\, which will be held online on 28 and 30 September 2021. Check out the full agenda and read the presentation abstracts. This fully virtual event will provide key updates on vaccines being developed for Shigella\, (ETEC) and other emerging diarrheal pathogens\, such as non-typhoidal Salmonella. \nClick here to learn more.
URL:https://carb-x.org/event/the-vaccines-against-shigella-and-etec-vase-conference/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210915T100000
DTEND;TZID=America/New_York:20210915T110000
DTSTAMP:20260504T133350
CREATED:20210903T133040Z
LAST-MODIFIED:20210903T133040Z
UID:5579-1631700000-1631703600@carb-x.org
SUMMARY:BLUE KNIGHT™ Webinar: Antimicrobial Resistance – Breakthrough Innovation and  Breaking Barriers
DESCRIPTION:As multi-drug resistant bacteria become increasingly threatening to global public health and existing antibiotics are becoming ineffective\, the global community of public and private organizations and life science innovators are rallying around the Antimicrobial Resistance challenge. \nJohnson & Johnson Innovation has invited leading experts in the field to share their views. Why aren’t (enough) new antibiotics being developed to address the AMR challenge? What other innovations might help without increasing antibiotic resistance? \nJoin the discussion as thought leaders share their views on the challenges surrounding this global health threat and the potential solutions. \nTopics will include: \n\nPriority MDR bacterial pathogens of interest\nPotential interventions to prevent and treat MDR bacterial infections\nBarriers in the development and commercialization pathway\nThe need for policy change to address these barriers\nThe potential roles of various organizations and public-private partnerships\n\n*This program is part of BLUE KNIGHT™\, a collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA). \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/blue-knight-webinar-antimicrobial-resistance-breakthrough-innovation-and-breaking-barriers/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210830
DTEND;VALUE=DATE:20210902
DTSTAMP:20260504T133350
CREATED:20210714T144516Z
LAST-MODIFIED:20210714T144516Z
UID:5523-1630281600-1630540799@carb-x.org
SUMMARY:Public Workshop: Science and Regulation of Bacteriophage Therapy
DESCRIPTION:The Food and Drug Administration (FDA)\, Center for Biologics Evaluation and Research\, and the National Institutes of Health\, National Institute of Allergy and Infectious Diseases are announcing a public workshop entitled “Science and Regulation of Bacteriophage Therapy.” The purpose of the public workshop is to exchange information with the medical and scientific community about the regulatory and scientific issues associated with bacteriophage therapy. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/public-workshop-science-and-regulation-of-bacteriophage-therapy/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210824T080000
DTEND;TZID=America/New_York:20210826T170000
DTSTAMP:20260504T133350
CREATED:20210824T161737Z
LAST-MODIFIED:20210824T161737Z
UID:5563-1629792000-1629997200@carb-x.org
SUMMARY:BIOCOM 5th AMR Conference 2021 ­– Summer Edition: AMR Briefing Sessions
DESCRIPTION:The #AMRconference is a platform for SMEs\, start-ups\, big pharma\, academia\, investors and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market. \nThe “AMR Conference” was started in 2017 as part of the annual “Berlin Conference on Life Sciences” series which was established by BIOCOM AG twelve years ago as an event format to discuss the challenges of SME-driven innovation for the health market and to offer a platform for meeting experts from business\, science\, clinics\, finance\, regulatory affairs and intellectual property. \nEach day will offer an AMR briefing session in the afternoon (starting at 2pm CET) on a dedicated topic\, including live speakers\, high-level panel discussions\, and interactive exchange with the audience: \n\nDay 1 – Status quo & COVID-19 Impact: What has changed after one year of COVID?\nDay 2 – Financing & Investing: What’s new with funds\, incubators and accelerators?\nDay 3 – Policy & Incentives: What can we learn from best practices to go ahead?\n\nCARB-X participants include Erin Duffy\, Chief of R&D\, who is a speaker on the session “Focus on incubators and public-private accelerators in US and Europe – How they drive the AMR innovation pipeline” on Wednesday\, August 25th at 3:00 p.m. – 4:15 p.m. CEST\, and Kevin Outterson\, Executive Director\, who is a speaker on the session “What can we expect and learn from the US and UK pull incentive initiatives?” on Thursday\, August 26th at 02:00 p.m. – 03:15 p.m. CEST \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/biocom-5th-amr-conference-2021-summer-edition-amr-briefing-sessions/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210722T110000
DTEND;TZID=America/New_York:20210722T130000
DTSTAMP:20260504T133350
CREATED:20210720T161444Z
LAST-MODIFIED:20210720T161836Z
UID:5529-1626951600-1626958800@carb-x.org
SUMMARY:Innovations for Tackling Tuberculosis in the Time of COVID-19: A Two-Part Virtual Workshop
DESCRIPTION:Register now: Innovations for Tackling Tuberculosis in the Time of COVID-19: Part One of a Two-Part Workshop (July 22\, 11 AM – 1 PM ET) \nThis public workshop is the first in a two-part series that examines the innovations needed to meet the targets for ending tuberculosis (TB) set by the WHO End TB Strategy for 2030 and affirmed by the United Nations High-Level Meeting on the Fight Against Tuberculosis. The workshop will feature presentations and discussions that will consider emerging technologies in diagnostic testing and vaccine development\, improvements in TB treatment\, and how to ensure increased and sustained commitments to reach the goal of ending TB in high burden countries despite the challenges from COVID-19. \nThis first session will provide an update on the current status\, unmet needs\, and promising advances in diagnostics\, vaccines and therapeutics\, and the critical need for new business models in sustainably combating TB. \nCARB-X participants include Kevin Outterson\, Executive Director\, who will be a speaker during the workshop.  \n\n\n\nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/innovations-for-tackling-tuberculosis-in-the-time-of-covid-19-a-two-part-virtual-workshop/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210705T080000
DTEND;TZID=America/New_York:20210705T120000
DTSTAMP:20260504T133350
CREATED:20210623T175205Z
LAST-MODIFIED:20210623T175205Z
UID:5481-1625472000-1625486400@carb-x.org
SUMMARY:Advances in Antimicrobial Innovation Scientific meeting
DESCRIPTION:This Royal Society conference will bring together scientists\, medical practitioners and funding bodies to raise awareness and interest for new anti-microbial advances. \nAnti-microbial resistance continues to grow as a worldwide health challenge. Pathogens are continually evolving to combat drugs given to treat potentially life-threatening diseases\, rendering treatments ineffective and threatening the many advances in fighting microbes over recent decades. \nAs therapeutics in current use become less effective\, new approaches are required. This event aims to raise awareness and interest for new anti-microbial advances\, the challenges faced in market delivery\, and their appropriate use in healthcare systems. \nAbout the conference series:\nThe conference is part of the Royal Society’s Transforming our future conferences in the life sciences\, supported by AstraZeneca. These meetings are unique\, high-level events that address the scientific and technical challenges of the next decade. Each conference features cutting edge science from industry and academia and brings together leading experts from the scientific community\, including regulatory\, charity and funding bodies. This conference also forms part of the Academy of Medical Sciences’ FORUM programme. \nCARB-X participants include Erin Duffy\, Chief of R&D\, who will participate in the session ‘Challenges of prescribing\, diagnostics and antibiotic education\, investment and building a business model for new antibiotics’ between 3.30pm – 4.30pm EST. \nClick here to learn more.\nClick here to register.
URL:https://carb-x.org/event/advances-in-antimicrobial-innovation-scientific-meeting/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210701
DTSTAMP:20260504T133350
CREATED:20210623T180031Z
LAST-MODIFIED:20210623T180135Z
UID:5483-1624924800-1625097599@carb-x.org
SUMMARY:Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) Virtual Public Meeting
DESCRIPTION:The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) provides advice\, information\, and recommendations to the Secretary regarding programs and policies intended to support and evaluate the implementation of U.S. government activities related to combating antibiotic-resistant bacteria.\n\n\n\n\n\n\nAt the June 29-30\, 2021 Virtual Public Meeting\, the PACCARB will deliberate and vote on two reports to transmit to the Secretary of Health and Human Services\, the first from the Disparities in Antibiotics Access and Use Working Group\, and the second from the Working Group on Antimicrobial Resistance (AMR) in Inter-Professional Education. The remainder of the 2-day public meeting will include an update on the status of the antibiotic development pipeline and an open council discussion on provocative questions in AMR (no recommendations will be made)\, in addition to presentations on Operationalizing One Health and the Environmental Dimensions of AMR. \nDate and Time:\nJune 29\, 2021 | 10:00 a.m. – 3:00 p.m. ET\nJune 30\, 2021 | 10:00 a.m. – 3:00 p.m. ET \n\n\n\n\n\nCARB-X participants include Kevin Outterson\, Executive Director\, who will be leading a session titled “THE ANTIBIOTICS PIPELINE: PAST\, PRESENT\, AND FUTURE” on June 29th at 12.05pm ET. \nClick here to learn more. \nClick here to view the agenda.\nClick here to view a live stream of the event.
URL:https://carb-x.org/event/presidential-advisory-council-on-combating-antibiotic-resistant-bacteria-paccarb-virtual-public-meeting/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210701
DTSTAMP:20260504T133350
CREATED:20210127T232452Z
LAST-MODIFIED:20210127T232452Z
UID:4904-1624924800-1625097599@carb-x.org
SUMMARY:ICAAR 2021: 15. International Conference on Antibiotics and Antibiotic Resistance
DESCRIPTION:The International Research Conference is a federated organization dedicated to bringing together a significant number of diverse scholarly events for presentation within the conference program. Events will run over a span of time during the conference depending on the number and length of the presentations. With its high quality\, it provides an exceptional value for students\, academics and industry researchers. \nICAAR 2021: 15. International Conference on Antibiotics and Antibiotic Resistance aims to bring together leading academic scientists\, researchers and research scholars to exchange and share their experiences and research results on all aspects of Antibiotics and Antibiotic Resistance. It also provides a premier interdisciplinary platform for researchers\, practitioners and educators to present and discuss the most recent innovations\, trends\, and concerns as well as practical challenges encountered and solutions adopted in the fields of Antibiotics and Antibiotic Resistance \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/icaar-2021-15-international-conference-on-antibiotics-and-antibiotic-resistance/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210627
DTEND;VALUE=DATE:20210630
DTSTAMP:20260504T133350
CREATED:20201203T013118Z
LAST-MODIFIED:20210309T184902Z
UID:4703-1624752000-1625011199@carb-x.org
SUMMARY:8th International Human Microbiome Congress (IHMC 2020)
DESCRIPTION:In June 2021\, the 8th International Human Microbiome Consortium Meeting will include a fully digital format. By doing this we can ensure compliance of healthy and safety measures\, and we can guarantee participation from our delegates. \nWith the support of the IHMC board\, a strong local Organizing Committee and a Scientific Committee composed of the most renowned scientists and researchers in the Microbiota field\, the Congress expects to attract a large international audience of over 1\,000 delegates. \nThe program will include the latest scientific developments and a variety of activities of interest for early stage to senior researchers\, clinical professionals\, academia\, the industry as well as the general public. Commercial stands will be also featured for the duration of the congress to foster networking and commercial opportunities among companies and delegates attending the event. The event will be accredited to provide Credits for Continuing Medical Education (EACCME) and will be structured around plenary sessions in the morning and parallel sessions\, symposia and satellite events for companies in the afternoon. \nThe event will also include the 7th edition of the Barcelona Debates on the Human Microbiome\, from microbes to human\, a meeting where the most recent studies on the complex human-microbiome relationship and how the microbiome can influence in improving the clinical practices are discussed. \nThe day the Congress starts\, Saturday 27th of June\, coincides with the World Microbiome Day. To celebrate this day\, a variety of activities will be organized and will be open to the general public to broaden their awareness of the microbiome and their effects. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/8th-international-human-microbiome-congress-ihmc-2020/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210622
DTEND;VALUE=DATE:20210624
DTSTAMP:20260504T133350
CREATED:20210316T151707Z
LAST-MODIFIED:20210316T151707Z
UID:5168-1624320000-1624492799@carb-x.org
SUMMARY:Sepsis Tech & Innovation 2021
DESCRIPTION:Following the success of the inaugural Sepsis Alliance Summit in 2020\, Sepsis Alliance is proud to announce the inaugural Sepsis Tech & Innovation virtual conference. Engage with the nation’s leading innovators\, clinicians\, investors\, and policymakers to discuss health technology and innovation\, and its tremendous potential to reduce the burden of sepsis. \nCatapulting off of Sepsis Alliance’s successful 2020 Sepsis Alliance Summit with more than 4\,000 registered attendees\, Sepsis Tech and Innovation is a very exciting opportunity for Sepsis Alliance to expand its voice in the health innovation and technology space. Our ultimate goal is to help take the costly guesswork out of sepsis diagnosis and care. In addition to education and training\, technology and innovation are critical to achieving major progress in reducing the burden of sepsis\, both in terms of lives lost and resources spent. Sepsis may be the best opportunity to leverage tech and innovation to save lives and reduce health spending in the nation. Sepsis Alliance is proud to offer Sepsis Tech & Innovation at no charge to participants. \nCARB-X participants include Erin Duffy\, Chief of Research and Development\, who will be leading the session “Therapeutics: Innovation and Challenges in the Fight Against AMR” on June 23\, 12:40pm – 1:10pm ET.   \nClick here to learn more.\nClick here to register.
URL:https://carb-x.org/event/sepsis-tech-innovation-2021/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210504
DTEND;VALUE=DATE:20210507
DTSTAMP:20260504T133350
CREATED:20201203T010043Z
LAST-MODIFIED:20210216T161720Z
UID:4697-1620086400-1620345599@carb-x.org
SUMMARY:World Vaccine Congress Washington 2021
DESCRIPTION:For the past 20 years\, the World Vaccine Congress Washington congress has evolved and grown into the leading vaccines congress globally\, with hundreds of speakers\, thousands of attendees and hundreds of networking opportunities. Our event format allows for whole-sector topics\, giving an opportunity for people to find out more about their specific area of research and their job-function. By running parallel niche conference channels over the 3 days\, it increases the relevance of the whole event for everyone who attends. \n\nCancer Immunotherapy\nImmune Profiling\nRespiratory Vaccines\nEmerging & Infectious Diseases\nClinical Trials\nVaccine Partnerships\nBioprocessing & Manufacturing\nVaccines Safety\nLogistics\nVeterinary Vaccines\nPartnerships\n\nDuring these sessions you will learn how cutting-edge research efforts can be integrated with pharma\, biotech\, academia and government to produce more and better vaccines to the market. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/world-vaccine-congress-washington-2021/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210420
DTEND;VALUE=DATE:20210423
DTSTAMP:20260504T133350
CREATED:20201202T224742Z
LAST-MODIFIED:20210216T142945Z
UID:4658-1618876800-1619135999@carb-x.org
SUMMARY:Anti-Infectives Drug Development Summit
DESCRIPTION:Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater\, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments\, biopharma\, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance. \nWith some now considering the field as the new ‘Wall Street darling’\, especially given the $1 billion launch of the AMR action fund\, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs. \nBringing together 60+ senior leaders from large pharma\, innovative biotech\, academia and investment companies\, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates\, novel modalities and effective strategies\, that address market sustainability and aim for superiority. \nCARB-X participants include Kevin Outterson\, Executive Director\, who will be leading the session “Surviving FDA Approval of your Antibiotic” on Wednesday April 21 at 9:25am ET / 6:25am PDT.  He will touch upon: \n\nWhat can we learn from the past decade of FDA antibiotic approvals? •\nNiche markets where your drug can differentiate from generics\nNon-dilutive funding: CARB-X\, BARDA\, HERA\nExit: AMR Action Fund\, PASTEUR\n\nCARB-X funded companies participating include Peptilogics\, Vedanta\, Antabio\, Bioversys\, ContraFect\, Locus\, Techulon\, Summit\, and MicuRx. \nClick here to learn more.\nClick here to view the event guide.\nClick here to register.
URL:https://carb-x.org/event/anti-infectives-drug-development-summit/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210413
DTEND;VALUE=DATE:20210417
DTSTAMP:20260504T133350
CREATED:20210210T173700Z
LAST-MODIFIED:20210210T173700Z
UID:4988-1618272000-1618617599@carb-x.org
SUMMARY:SHEA Spring 2021 Conference
DESCRIPTION:Who should come to SHEA Spring 2021?\nSHEA members and non-members of all disciplines relating to Infection Prevention Programs\, Antibiotic Stewardship Programs\, Public Health\, Pharmacy\, Occupational Health\, Clinical Microbiology\, Quality Improvement\, and Patient Safety. If you are involved in infection prevention or infection control you need to be at SHEA Spring 2021! \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/shea-spring-2021-conference/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210325T120000
DTEND;TZID=America/New_York:20210325T130000
DTSTAMP:20260504T133350
CREATED:20210317T172121Z
LAST-MODIFIED:20210317T172121Z
UID:5174-1616673600-1616677200@carb-x.org
SUMMARY:The Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance at Tufts (Levy CIMAR) Monthly Science Meeting: Innovation Solutions to AMR
DESCRIPTION:Please join us on Thursday\, March 25th\, at noon for this month’s Levy CIMAR Science Meeting on “Innovation Solutions to AMR.” We are excited to hear from Kevin Outterson\, Esq.\, Professor of Law at Boston University and Executive Director of the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator\, or CARB-X. CARB-X is a global partnership hosted at BU Law that is focused on supporting developers of promising new antibiotics\, diagnostics\, and vaccines that tackle the threat of untreatable bacterial infections. \nCARB-X participants include Kevin Outterson\, Executive Director. \nClick here to learn more about Levy CIMAR.\nContact Rima Mycynek @ Rima.Mycynek@tufts.edu for Zoom Details.
URL:https://carb-x.org/event/the-stuart-b-levy-center-for-integrated-management-of-antimicrobial-resistance-at-tufts-levy-cimar-monthly-science-meeting-innovation-solutions-to-amr/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210323
DTEND;VALUE=DATE:20210325
DTSTAMP:20260504T133350
CREATED:20201203T003554Z
LAST-MODIFIED:20201203T003554Z
UID:4682-1616457600-1616630399@carb-x.org
SUMMARY:3rd Bacteriophage Therapy Summit 2021
DESCRIPTION:The 3rd Bacteriophage Therapy Summit returns! With a new looking speaker line-up and never before seen content\, we are excited to continue to unite the community to progress fundamental bacteriophage research into clinically-significant products. \nThe overuse of antibiotics had led to the development of multi-resistant bacterial strains\, most notably ESKAPE pathogens\, rendering the use of antibiotics\, which in many scenarios are useless. However\, bacteriophages may hold the key in overcoming the global antibiotic resistance crisis. \nAlthough the potential use of phage and phage-derived products in a clinical setting is beginning to be understood\, there still remains a number of unique challenges associated with this novel therapeutic agent. A developing regulatory landscape\, up-scaling of manufacturing processes\, and the design of clinical trials are just a few of the roadblocks holding back development. \nBringing together leading drug developers\, academics and clinical researchers\, our agenda is focused to address the main translation challenges from characterization of phages through to clinical development. This is your opportunity to join your peers to strengthen your product development pipelines and forge new collaborations to unlock the full potential of bacteriophage therapeutics. \nCARB-X participants include Richard Alm\, Alliance Director. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/3rd-bacteriophage-therapy-summit-2021/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210312T110000
DTEND;TZID=America/New_York:20210312T130000
DTSTAMP:20260504T133350
CREATED:20201203T001344Z
LAST-MODIFIED:20210210T172607Z
UID:4678-1615546800-1615554000@carb-x.org
SUMMARY:BARDA AMR Vaccine Public Workshop: Vaccines against AMR Threats
DESCRIPTION:Multi-drug resistant (MDR) organisms are a threat to national security and public health. As rates of antimicrobial resistance (AMR) in pathogens continue to increase new therapeutics and vaccines are essential to combat the growing crisis.  Every year\, 2.8 million American develop a drug resistant infection and 35\,000 people die. Globally\, MDR infections kill 700\,000 each year – current estimates are that MDR organisms will kill more than 10 million a year by 2050 if left unchecked. \nBARDA supports development and procurement of medical countermeasures to protect Americans against chemical\, biological\, radiological\, and nuclear (CBRN) threats. MDR does not discriminate\, and victims of CBRN events are at risk of suffering fatal complications from drug resistant infections. One of BARDA’s top priorities is to develop a vaccine to protect people from these threats. \nHelp BARDA fight AMR! Join the workshop to learn more about BARDA\, our mission\, and how we plan to tackle this growing threat. The event will consist of presentations from BARDA experts\, followed by a structured discussion\, and Q&A. Companies and others interested in working with BARDA are encouraged to attend the March 12\, 2021 workshop. The event is open to the public\, but space is limited. Be sure to register by March 5\, 2021. Please\, no more than four people from one organization. Are you a product developer working on a vaccine against one of the four targeted pathogens? Then we want to talk with you! Be sure to request a private meeting when you register for the workshop. \nCARB-X participants include Kevin Outterson\, Executive Director. \nClick here to learn more.\nClick here to register.
URL:https://carb-x.org/event/pandemic-prevention-and-innovation-summit-identifying-opportunities-for-investment-collaboration-in-ensuring-future-pandemic-preparedness/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210304T100000
DTEND;TZID=America/New_York:20210304T113000
DTSTAMP:20260504T133350
CREATED:20210223T151424Z
LAST-MODIFIED:20210223T151424Z
UID:5022-1614852000-1614857400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Learning from COVID-19 to tackle the silent pandemic of antibiotic resistance
DESCRIPTION:The COVID-19 pandemic has brought into sharp focus the impact of pandemics. The novel coronavirus has claimed more than a million lives\, trillions of dollars have been lost\, expenditures cut and international efforts to achieve the Sustainable Development Goals put in jeopardy. \nCOVID-19 has demonstrated pandemic preparedness requires a global coordinated effort\, and no country can do it alone. Strengthening our ability to fight the silent pandemic of drug-resistant infections must also ensure affordable access to vital health tools\, including new and improved treatments. This webinar will focus on how we can apply the lessons learned from COVID-19 to tackle drug resistance and ensure access to appropriate antibiotics. \nSpeakers:  \n\nManica Balasegaram\, GARDP\nJoanne Liu\, University of Montreal and Médecins Sans Frontières\nMarc Mendelson\, Groote Schuur Hospital\, University of Cape Town\n\nModerator: Claire Doole \nThe presentations will be followed by a Q&A session. \nClick here to learn more and register.
URL:https://carb-x.org/event/live-webinar-gardp-revive-learning-from-covid-19-to-tackle-the-silent-pandemic-of-antibiotic-resistance/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210224
DTEND;VALUE=DATE:20210227
DTSTAMP:20260504T133350
CREATED:20201202T235219Z
LAST-MODIFIED:20201202T235219Z
UID:4677-1614124800-1614383999@carb-x.org
SUMMARY:Phage Futures Congress
DESCRIPTION:Join us at the International Phage Futures Congress in 2021\, as we create a virtual stage upon which to initiate all-important discussions & forge partnerships between key stakeholders from all over the world. Experts in their respective fields will discuss how to translate new phage-based applications into clinical studies & beyond. Discover how you can be at the forefront of the developing phage therapy market. Network & learn from established biotech companies\, emerging start-ups\, leading academics\, global accelerator representatives\, investment firms\, international healthcare organisations & regulatory bodies. \nAmong other topics\, expect to hear & participate in: \n\nAdvice on how to successfully navigate clinical trial progression to prove efficacy along with recent developments from leading biotechs in phage therapeutic trials targeting chronic & acute illnesses.\nRegulatory discussions between international governing bodies with region specific follow-up conversations with the experts.\nInsights into new fields for phage application\, such as oncology\, diagnostics & microbial gene therapy.\nExpert advice on how to find & secure financial investments.\n\nCARB-X participants include Richard Alm\, Alliance Director. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/phage-futures-congress/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210222
DTEND;VALUE=DATE:20210227
DTSTAMP:20260504T133350
CREATED:20210216T143312Z
LAST-MODIFIED:20210216T143312Z
UID:4998-1613952000-1614383999@carb-x.org
SUMMARY:The Bloomsbury SET Conference on Infectious Disease and AMR
DESCRIPTION:The Bloomsbury SET is hosting its first virtual conference focused on knowledge exchange and infectious disease during the 22nd to 26th February 2021. \nThroughout the week\, the Bloomsbury SET and wider partners will explore interdisciplinary innovation\, research translation\, commercialisation\, impact and connecting capabilities to tackle global health challenges through knowledge exchange.  \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/the-bloomsbury-set-conference-on-infectious-disease-and-amr/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210202T100000
DTEND;TZID=America/New_York:20210202T120000
DTSTAMP:20260504T133350
CREATED:20210127T225936Z
LAST-MODIFIED:20210127T230630Z
UID:4898-1612260000-1612267200@carb-x.org
SUMMARY:C-CAMP AMR Webinar Series: Pre-Clinical and Early Drug Development in India
DESCRIPTION:India is fast emerging as one of the global hubs for conducting pre- clinical and clinical development. The webinar will showcase the competencies of some of the CROs\nin India and how Product Developers can leverage the advantages of working with Indian CROs.  \nParticipating CROs include: \n\nBioneeds India\nSyngene International\nSIRO Clinpharm\nSai Life Sciences\nGVK Bio\n\nClick here to learn more and register.\nClick here to view the zoom link.
URL:https://carb-x.org/event/c-camp-amr-webinar-series-pre-clinical-and-early-drug-development-in-india/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210202
DTEND;VALUE=DATE:20210204
DTSTAMP:20260504T133350
CREATED:20201203T002040Z
LAST-MODIFIED:20201203T002040Z
UID:4679-1612224000-1612396799@carb-x.org
SUMMARY:BSAC/GARDP Antimicrobial Chemotherapy Virtual Conference 2021
DESCRIPTION:Jointly organised by the BSAC and GARDP. For 2021\, the conference collaborators are the Helmholtz Institute for Pharmaceutical Sciences (HIPS)\, the German Center for Infection Research (DZIF) and the International Research Alliance for Antibiotic Discovery and Development (IRAADD) (a JPIAMR funded network) \nClick here to learn more.\nClick here to register.
URL:https://carb-x.org/event/bsac-gardp-antimicrobial-chemotherapy-virtual-conference-2021/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210126
DTEND;VALUE=DATE:20210129
DTSTAMP:20260504T133350
CREATED:20201202T234806Z
LAST-MODIFIED:20201207T214811Z
UID:4670-1611619200-1611878399@carb-x.org
SUMMARY:4th Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference
DESCRIPTION:Please make plans to join us for this outstanding line-up of internationally-renowned experts in antimicrobial resistance and stewardship. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/skip-to-content-4th-annual-texas-medical-center-antimicrobial-resistance-and-stewardship-conference/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210121
DTEND;VALUE=DATE:20210122
DTSTAMP:20260504T133350
CREATED:20201202T233345Z
LAST-MODIFIED:20201207T214641Z
UID:4666-1611187200-1611273599@carb-x.org
SUMMARY:Innovative Medicines Initiative (IMI) ENABLE Annual Meeting
DESCRIPTION:Antimicrobial resistance (AMR) is a major public health threat. Infections caused by resistant bacteria are increasing and causing Europe to face soaring costs both in terms of lives and public health expenditure. Despite the strong need for new antimicrobials\, very few new\, effective antibiotics have been brought to the market in the last decades. The ENABLE project\, within IMI’s New Drugs for Bad Bugs (ND4BB) programme\, is working to advance the development of potential antibiotics against Gram-negative bacteria\, such as Escherichia coli. The ultimate goal of the project is to develop attractive antimicrobial candidates for testing in the clinic\, bringing the possibility of new antibiotics to treat Gram-negative infections one step closer to patients. \nCARB-X participants include Erin Duffy\, Chief of R&D.  \nClick here to learn more.
URL:https://carb-x.org/event/innovative-medicines-initiative-imi-enable-annual-meeting-emd/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210118
DTEND;VALUE=DATE:20210121
DTSTAMP:20260504T133350
CREATED:20201202T234358Z
LAST-MODIFIED:20201202T234358Z
UID:4671-1610928000-1611187199@carb-x.org
SUMMARY:Keystone Symposia: Harnessing the Microbiome for Disease Prevention and Therapy
DESCRIPTION:Joint meeting with: The Microbiome: From Mother to Child\nJanuary 18-20\, 2021 | 10:00AM EST | 3:00PM UTC | 4:00PM CET* \nOur understanding of the microbiome is advancing rapidly\, and continues to productively move through the discovery phase\, with numerous correlations being established between specific commensal microbes or microbiota compositions and a wide range of diseases that includes infections\, inflammatory conditions\, metabolic disease\, autoimmunity and neurologic syndromes. The initial discovery of these potentially important correlations has led many laboratories around the world to probe the molecular mechanisms that form the causal link between specific commensal microbes and disease development\, progression and resolution. Although there have been great advances\, culturing many of the prevalent and metabolically active obligate anaerobic commensals remains a challenge. Exciting advances\, however\, are emerging from laboratories developing tools to genetically manipulate key commensal organisms\, facilitating experimental studies that are identifying the small\, bioactive molecules they produce\, some of which have therapeutic potential. Studies of the impact of bacteriophage on the microbiota also suggest that they may have therapeutic potential. This Keystone conference will focus on recent advances that demonstrate\, at the cellular and molecular level\, the impact of the microbiota and its products on disease susceptibility/resistance\, with an emphasis on microbial and host metabolism\, inter-microbial interactions and the amelioration of diseases. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/keystone-symposia-harnessing-the-microbiome-for-disease-prevention-and-therapy/
LOCATION:VIRTUAL EVENT
END:VEVENT
END:VCALENDAR